Characterization of biomarkers on circulating tumor cells to guide therapy

循环肿瘤细胞生物标志物的表征以指导治疗

• 批准号: 8056722
• 负责人: Richard H. Bruce
• 金额: $ 19.83万
• 依托单位: KRYPTOS MEDICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-27 至 2012-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8056722
• 关键词: Characterization; biomarkers; circulating; tumor; cells

DESCRIPTION (provided by applicant): Breast cancer-related death results from complications due to metastatic growth. Therapies for metastatic patients focus on extending survival and controlling symptoms, and the choice of therapies is frequently based on particular target-proteins found in the primary breast tumor, which is usually excised years before development of metastatic disease. Therapies for these target-proteins are much more effective in treating metastatic patients than standard chemotherapy. Because cancer changes over the time, the target-proteins in some metastatic tumors could well have changed from levels on the primary tumor. Biopsies that could test target proteins levels in metastatic tissue pose a problem because they are invasive, pose risk to the patient and are infeasible for patients with multiple different tumor sites. This proposal addresses locating tumor cells circulating in the blood and testing them for the target-proteins that help selection of a therapy. Because, circulating tumor cells (CTCs) represent the current metastatic disease, they arguably better represent metastatic disease than the primary tumor. Circulating tumor cells are rare and difficult to find. Current technologies used to find CTCs have problems. Some miss certain types of tumor cells due to low levels of expression of the enrichment target and provide poor images of the cells making it hard to be sure that they are CTCs. Others rely on size to find CTCs, but size varies widely, and such technologies miss small CTCs. In this work a research instrument, the FAST cytometer, uses an enrichment target that is known to be expressed at high levels in solid tumor cells. The assay does not degrade the cell morphology, and imaging is done on a planar surface for high fidelity. This proposal addresses the work needed to transform the research instrument into an instrument approved for use in a clinical trial. Methods will be developed to monitor the accuracy of the instrument and the multiplex assay. Procedures will be established to enable the CLIA certification needed for the clinical trial. The clinical trial will focus on metastatic breast cancer patients who have a triple negative primary tumor. Patients with this tumor type have no target-proteins and are ineligible to receive the targeted therapies. Consequently, they face a much poorer outcome. Preliminary data with a multiplex assay for 3 target-proteins has shown that target-proteins on CTCs are present in a significant number of patients. The clinical trial in Phase II will determine if these patients survive longer when the relevant target-therapies are administered. Clinical validation of the use of target protein levels on CTCs should enable more effective and personalized targeted therapy and prevention of acquired drug resistance, resulting in better response, improved progression-free and better overall survival. PUBLIC HEALTH RELEVANCE: Metastatic breast cancer can be optimally treated with special therapies that are selected by the presence of related proteins in the primary breast tumor, which is usually excised years before development of metastatic disease. As cancer is known to change over the time, the proteins in metastatic tumors could well be different. This proposal seeks to locate tumor cells circulating in the blood and determine in a clinical trial whether their proteins can better guide the selection of a therapy. The trial will focus on patients who have no special proteins on their primary tumors and hence face a worse outcome.

描述（由申请人提供）：乳腺癌相关死亡由转移性生长引起的并发症引起。转移性患者的治疗侧重于延长生存期和控制症状，并且治疗的选择通常基于在原发性乳腺肿瘤中发现的特定靶蛋白，其通常在转移性疾病发展前数年切除。针对这些靶蛋白的疗法在治疗转移性患者方面比标准化疗有效得多。由于癌症随着时间的推移而变化，一些转移性肿瘤中的靶蛋白很可能与原发性肿瘤的水平不同。可以检测转移组织中靶蛋白水平的活检会带来问题，因为它们是侵入性的，对患者构成风险，并且对于具有多个不同肿瘤部位的患者是不可行的。该提案旨在定位血液中循环的肿瘤细胞，并测试它们的靶蛋白，以帮助选择治疗方法。因为循环肿瘤细胞（CTC）代表了当前的转移性疾病，所以它们可以说比原发性肿瘤更好地代表了转移性疾病。循环肿瘤细胞是罕见的，很难找到。目前用于寻找CTC的技术存在问题。由于富集靶标的低水平表达，一些错过了某些类型的肿瘤细胞，并提供了细胞的差图像，使得难以确定它们是CTC。其他人依靠大小来寻找CTC，但大小差异很大，这些技术错过了小CTC。在这项工作中，研究仪器FAST细胞仪使用了一种已知在实体瘤细胞中高水平表达的富集靶点。该测定不会降低细胞形态，并且在平面表面上进行成像以获得高保真度。本提案涉及将研究仪器转换为批准用于临床试验的仪器所需的工作。将开发方法来监测仪器和多重测定的准确度。将建立程序，以实现临床试验所需的CLIA认证。该临床试验将重点关注患有三阴性原发性肿瘤的转移性乳腺癌患者。这种肿瘤类型的患者没有靶蛋白，不适合接受靶向治疗。因此，他们面临的结果要差得多。针对3种靶蛋白的多重测定的初步数据显示，CTC上的靶蛋白存在于大量患者中。II期临床试验将确定这些患者在接受相关靶向治疗后是否存活更长时间。临床验证使用CTC上的靶蛋白水平应该能够实现更有效和个性化的靶向治疗和预防获得性耐药性，从而产生更好的反应，改善无进展和更好的总生存期。 公共卫生相关性：转移性乳腺癌可以用特殊疗法进行最佳治疗，这些疗法是根据原发性乳腺肿瘤中相关蛋白的存在而选择的，这些原发性乳腺肿瘤通常在转移性疾病发生前数年切除。众所周知，癌症会随着时间的推移而发生变化，因此转移性肿瘤中的蛋白质可能会有所不同。该提案旨在定位血液中循环的肿瘤细胞，并在临床试验中确定其蛋白质是否可以更好地指导治疗的选择。该试验将重点关注原发肿瘤上没有特殊蛋白质的患者，因此面临更糟糕的结果。